Etoricoxib in Patients With Parkinsonian Disease
ConditionParkinson Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age50-70
SponsorIhab Elsayed Hassan
About this trial
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years.
Both male and female will be included.
Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.
Disqualifiers
Breast feeding
Patients with significant liver and kidney function abnormalities.
Alcohol and / or drug abusers.
Patients with known allergy to the study medications
Trial design
Design model
Parallel
Treatments tested in this trial
L-dopa
DrugLevodopa is the standard therapy in PD.
Etoricoxib
DrugEtoricoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1) and by the inducible COX-2 enzymes and are secreted mainly by astrocytes and microglia.
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Control groupActive comparator 1 intervention
Group B: Etoricoxib groupActive comparator 2 interventions
Trial outcomes
Primary outcomes
1
- Change in The Unified Parkinson's Disease Rating Scale
\- Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Ihab Elsayed Hassan
Lead sponsor
Tanta University
Sponsor institution
Source ClinicalTrials.gov